Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 14/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.36 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27166380 | 0.89 | MEN1 (0.45) | MERTKJAK3MEN1GABBR2CYP1A2 | |
| SCHEMBL27224889 | 0.86 | JAK1 (0.44) | MAPK8MAPK9MERTKJAK3JAK1 | |
| SCHEMBL14656638 | 0.82 | MAPK8 (0.54) | MAPK8MAPK9MERTKJAK3JAK1 | |
| SCHEMBL19857398 | 0.80 | MAPK8 (0.45) | MAPK8MAPK9MERTKJAK3JAK1 | |
| SCHEMBL23340803 | 0.79 | MAPK8 (0.67) | MAPK8MAPK9 | |
| SCHEMBL14657468 | 0.79 | MAPK8 (0.67) | MAPK8MAPK9 | |
| SCHEMBL28416204 | 0.77 | MAPK8 (0.51) | MAPK8MAPK9MERTK | |
| SCHEMBL19857335 | 0.77 | MERTK (0.43) | MAPK8MAPK9MERTKJAK3JAK1 | |
| SCHEMBL31153372 | 0.77 | MERTK (0.43) | MAPK8MAPK9MERTKJAK3JAK1 | |
| SCHEMBL14657356 | 0.75 | JAK1 (0.59) | MAPK8MAPK9JAK3JAK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | MAPK8 1163/4885MAPK9 1047/4885MERTK 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.